Iconovo (ICO)
Stockholm Exchange · Sweden · prices in SEK · close of 20 Oct 2026
Key indicators
| Last close | SEK 0.978 |
|---|---|
| 52-week range | 0.870 – 2.160 |
| Return, 1 month / 3 months | −20.8% / +3.6% |
| Return, 1 year / 3 years | −54.1% / −91.5% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 52.7% |
| Worst drawdown (1 year) | -56.4% |
| Average daily value traded | 0.08M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Iconovo is a Swedish company based in Lund that develops inhaler devices for delivering medicines to the lungs. It designs dry powder inhalers and other inhalation platforms, including single-dose and multi-dose devices, and works with pharmaceutical partners that use these devices with their own drug formulations. Its customers are mainly drug developers and healthcare companies that need reliable inhalation technology for respiratory and other treatments, and the company supports them through development and licensing arrangements.
The shares are listed on the Stockholm Exchange in Sweden under the code ICO, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Iconovo (ICO) trades on the Stockholm Exchange in Sweden. It last closed at SEK 0.978 on 20 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 641 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 54.1% and over the last three months it rose 3.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 41 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -14.6% | ||
| From 52-week high | -54.3% | ||
| Momentum | 40 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 3.6% | ||
| 6-month return | -15.7% | ||
| 12-month return, skipping the last month | -42.0% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 52.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -56.4% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.08M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.0% |
|---|---|
| 1 month | −20.8% |
| 3 months | +3.6% |
| 6 months | −15.7% |
| 1 year | −54.1% |
| 3 years | −91.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 1.194 / 1.145 |
|---|---|
| Golden / death cross (60 days) | Golden, 16 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.069 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.